X-ray co-crystal structure aminobenzimidazole triazine 1 bound to Lck
The structure was published by Martin, M.W., Newcomb, J., Nunes, J.J., et al., Ermann, M., Johnston, D., and Saluste, C.G., in 2008 in a paper entitled "Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity." (abstract).
This crystal structure was determined using X-ray diffraction at a resolution of 2.0 Å and deposited in 2008.
The experimental data on which the structure is based was not deposited.
The PDB entry contains the structure of Proto-oncogene tyrosine-protein kinase LCK. This molecule has the UniProt identifier P06239 (LCK_HUMAN). The sample contained 272 residues which is < 90% of the natural sequence. Out of 272 residues 270 were observed and are deposited in the PDB.
It also contains one or more heterogenic compounds (e.g., ligands, co-factors, ions, modified amino acids, etc.); see here for a complete list.
The molecule is most likely monomeric.
The following tables show cross-reference information to other databases (to obtain a list of all PDB entries sharing the same property or classification, click on the magnifying glass icon):
This entry contains 1 unique UniProt protein: